http://rdf.ncbi.nlm.nih.gov/pubchem/patent/NZ-522665-A
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_707efc20e3bf58b7b4bcb48eedea0bd4 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-22 |
filingDate | 2002-12-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c2dca2f2991e78fe72bb02b84d3522be |
publicationDate | 2004-04-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | NZ-522665-A |
titleOfInvention | Pharmaceutical composition inducing cancer cell differentiation and the use for treatment and prevention of cancer thereof |
abstract | A cell differentiation agent-II (CDA-II) purified from fresh human urine, that is effective for the therapy and prevention of cancer is disclosed. A common feature of cancer is that all cancer cells keep on dividing, and are unable to undergo terminal differentiation. Abnormal methylation enzymes are a major factor contributing to this unique feature. CDA-II is effective to convert abnormal methylation enzymes into normal enzymes, thus enabling cancer cells to undergo terminal differentiation, thereby eliminating the cause of the disease. Since the target is a cancer specific protein factor associated with methylation enzymes, the therapy is selective and without adverse side effects. Active components of CDA-II consist of differentiation inducers, helper inducers, and anticachexia agents. In addition, when CDA-II is employed in conjunction with thymidine a much better anticancer effect is achieved. |
isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2263681-A1 |
priorityDate | 2002-12-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1073.